Elisabetta Viscardi

Dr. Elisabetta Viscardi


Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 November 2019 in Cancers
Verified
Journal Article
Open access
PDF file
Matteo CassinaMatteo Cassina
Matteo Cassina
LFLuisa Frizziero
Luisa Frizziero
EOEnrico Opocher
Enrico Opocher
Raffaele ParrozzaniRaffaele Parrozzani
Raffaele Parrozzani
USUgo Sorrentino
Ugo Sorrentino
Eva TrevissonEva Trevisson
Eva Trevisson
Type 1 neurofibromatosis (NF1) is a dominantly inherited condition predisposing to tumor development. Optic pathway glioma (OPG) is the most frequent central nervous system tumor in children with NF1, affecting approximately 15–20% of patients. The lack of well-established prognostic markers and the wide clinical variability with respect to tumor progression and visual outcome make the clinical management of these tumors challenging, with significant differences among distinct centers. We reviewed published articles on OPG diagnostic protocol, follow-up and treatment in NF1. Cohorts of NF1 children with OPG reported in the literature and patients prospectively collected in our center were analyzed with regard to clinical data, tumor anatomical site, diagnostic workflow, treatment and outcome. In addition, we discussed the recent findings on the pathophysiology of OPG development in NF1. This review provides a comprehensive overview about the clinical management of NF1-associated OPG, focusing on the most recent advances from preclinical studies with genetically engineered models and the ongoing clinical trials.

12 March 2014 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
BBBruno De Bernardi
Bruno De Bernardi
LQlucia Quaglietta
lucia Quaglietta
RHRiccardo Haupt
Riccardo Haupt
ACAurora Castellano
Aurora Castellano
ETElisa Tirtei
Elisa Tirtei
AGAnna Rita Gigliotti
Anna Rita Gigliotti

1 August 1998 in Journal of Hematotherapy
Verified
Journal Article
Closed access
Lawrence FaulknerLawrence Faulkner
Lawrence Faulkner
VTVeronica Tintori
Veronica Tintori
ATAngela Tamburini
Angela Tamburini
APAntonella Paoli
Antonella Paoli
AGAlberto Garaventa
Alberto Garaventa
GBGabriella Bernini
Gabriella Bernini
High-sensitivity immunocytochemistry was used to evaluate the relative frequency of neuroblastoma cells in bone marrow and peripheral blood in patients with neuroblastoma (NB). A total of 51 concomitant paired blood and marrow samples (102 total) from 35 patients with NB (age 4 months-31 years; stage 29 stage IV, 4 stage III, 2 stage IVS; 14 at diagnosis, 18 in relapse, 12 during treatment, and 7 off-therapy) were analyzed. Cytospins containing up to 10(6) cells each were prepared using the mononuclear cell (MNC) fraction. For immunocytologic staining, a primary mouse monoclonal anti-GD2 antibody (3F8), a secondary antimouse biotinylated antibody, and a streptavidin-alkaline phosphatase complex were used. A minimum of two cytospins containing a mean of 1.4 x 10(6) total MNCs was analyzed in addition to a negative and a positive control. No circulating tumor cells were detected when the concomitant marrow samples were negative or had 10,000 NB cells per 10(6) MNC (1%), the concomitant blood sample was positive for 9 of the 10. When both marrow and blood samples were positive (15 BM-PB pairs), NB cell frequency was significantly lower in blood, with a mean difference of 2.14 logs (median 2.22, range -0.16-4.8, standard error 0.38). In patients with NB, circulating tumor cell frequencies seem to be substantially lower than in concomitant marrow samples, with a mean difference of >2 logs.

11 January 2019 in Italian Journal of Pediatrics
Verified
Journal Article
Open access
PDF file
BBBruno De Bernardi
Bruno De Bernardi
ACAndrea Di Cataldo
Andrea Di Cataldo
AGAlberto Garaventa
Alberto Garaventa
PMPaolo Massirio
Paolo Massirio
EVElisabetta Viscardi
Elisabetta Viscardi
RHRiccardo Haupt
Riccardo Haupt
Infants diagnosed with stage 4 s neuroblastoma commonly experience spontaneous disease regression, with few succumbing without response to therapy. We analyzed a large cohort of such infants enrolled in the Italian Neuroblastoma Registry to detect changes over time in presenting features, treatment and outcome. Of 3355 subjects aged 0–18 years with previously untreated neuroblastoma diagnosed between 1979 and 2013, a total of 280 infants (8.3%) had stage 4 s characteristics, 268 of whom were eligible for analyses. Three treatment eras were identified on the basis of based diagnostic and chemotherapy adopted. Group 1 patients received upfront chemotherapy; Group 2 and 3 patients underwent observation in the absence of life-threatening symptoms (LTS), except for Group 3 patients with amplified MYCN gene, who received more aggressive therapy. The three groups were comparable, with few exceptions. Ten-year overall survival significantly increased from 76.9 to 89.7% and was worse for male gender, age 0–29 days and presence of selected LTS on diagnosis, elevated LDH, and abnormal biologic features. Infants who underwent primary resection ± chemotherapy did significantly better. On multivariate analysis, treatment eras and the association of hepatomegaly to dyspnea were independently associated with worse outcome. Our data confirm that stage 4 s neuroblastoma is curable in nearly 90% of cases. Hepatomegaly associated to dyspnea was the most important independent risk factor. The cure rate could be further increased through timely identification of patients at risk who might benefit from surgical techniques, such as intra-arterial chemoembolization and/or liver transplantation, which must be carried out in institutions with specific expertise.

3 July 2007 in Child's Nervous System
Verified
Journal Article
Closed access
PDF file
SSStefano Sartori
Stefano Sartori
ALA. M. Laverda
A. M. Laverda
MCM. Calderone
M. Calderone
CCC. Carollo
C. Carollo
EVElisabetta Viscardi
Elisabetta Viscardi
Giorgio PerilongoGiorgio Perilongo
Giorgio Perilongo

4 April 2016 in Clinical and Translational Oncology
Verified
Journal Article
Closed access
PDF file
ACAndrea Di Cataldo
Andrea Di Cataldo
Antonella AgodiAntonella Agodi
Antonella Agodi
JBJ. Balaguer
J. Balaguer
AGAlberto Garaventa
Alberto Garaventa
Martina BarchittaMartina Barchitta
Martina Barchitta
ACAdela Cañete
Adela Cañete